Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCHW7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,269
Award facts
- Contract value 100% obligated
- $10,269.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $10,269.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of EXPAREL 266 mg/20 mL vials. This firm fixed-price delivery order was issued on January 21, 2026, with an ultimate completion date of February 11, 2026, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $499.9 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Defense Logistics Agency's Medical Supply Chain division, delivering a comprehensive range of products including branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals to support Department of Defense healthcare operations worldwide. The company's established performance across multiple delivery orders—ranging from under $100 to over $115,000—demonstrates its reliability as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy, which enables DLA to issue firm fixed-price delivery orders for recurring medical supply needs across military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FCHW7?
SPE2DR26FCHW7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FCHW7 worth?
The government has obligated $10,269 on SPE2DR26FCHW7.
Is contract SPE2DR26FCHW7 an order under another contract?
Yes. SPE2DR26FCHW7 is a delivery order under SPE2DR25D9113, an indefinite delivery contract.
Was contract SPE2DR26FCHW7 competed?
The extent of competition for SPE2DR26FCHW7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award